Getting you a comprehensive review of the product
Reading every ingredient in the formula…
Reading every ingredient in the formula…
Join The Clean Sheet™ community
Science-backed beauty tips, ingredient alerts, and early access. Straight to your WhatsApp.
Join for free →
This premium serum offers a well-formulated, clinically-backed approach to dark spot correction with strong active ingredients, delivering on its ambitious promises for those willing to invest.
₹3,999 • Analysed 21 July 2026
The La Roche-Posay Mela B3 Serum is positioned at a premium price point in the Indian market (Rs.3999 for 30ml). Its lightweight, silicone-enhanced texture is well-suited for India's often hot and humid climate, preventing a heavy feel. The strong claims of '85% reduction in dark spots' are highly relevant for Indian skin tones (Fitzpatrick III-V) which are prone to post-inflammatory hyperpigmentation, and these claims are backed by brand-cited clinical studies, aligning with ASCI's requirements for quantified claims.
Independent and free. The Clean Sheet takes no money from brands to review, rank, or approve a product. This is a web evidence review, not a Clean Sheet certification. We checked the ingredient list, publicly available test reports, marketing claims, and formula logic using only public information available at the time of review.
Supported by the presence of Niacinamide, Melasyl™, LHA, and Retinyl Palmitate, and brand's clinical study summary for dark spot reduction.
Brand states 'Clinically proven to reduce dark spots by 85% in 8 weeks' based on a clinical study summary.
Brand claims 'long-lasting efficacy' and 'prevents reappearance' based on clinical study summary, but specific data on prevention is less detailed than reduction.
Niacinamide is high in the INCI, consistent with 10% disclosure. Melasyl™ (2-Mercaptonicotinoyl Glycine) is also high in the INCI. Percentages are disclosed.
Brand states 'Clinically proven to reduce dark spots by 85% in 8 weeks' based on a clinical study summary.
Brand provides summary results of a clinical study (e.g., '85% reduction in 8 weeks'). Full study details (DOI, methodology) are not publicly linked on the Indian site, but summary is present.
Standard claim for LRP products, implying testing under dermatological supervision. Summary of testing is typically available from the brand.
Standard claim for LRP products, implying testing to ensure it does not clog pores. Summary of testing is typically available from the brand.
What we could confirm from public sources and the verified ingredient list.
Ingredient Safety & Toxicity
Full ingredient list retrieved and verified against INCIDecoder.
Screened against the ingredient database (16 of 32 ingredients matched); no cosmetics-prohibited ingredient found.
No ingredient with a recognised endocrine-activity concern found in the database.
No IARC-classified or formaldehyde-releasing ingredient found in the database screen.
No commonly-comedogenic ingredient found - a reasonable fit for acne-prone skin.
Irritation & Allergen Risk
Declares 1 known allergen(s) (Retinyl Palmitate). Reactive skin should note these.
No high-sensitisation preservative (MI/MCI/formaldehyde-releaser) from our screen was found.
Brand claims dermatologist testing (claim stated; underlying report not seen).
Ingredient Transparency
The full INCI list is publicly available, not just hero ingredients.
Active percentages are disclosed for the hero ingredient(s).
Any proprietary 'complex' is broken down into its actual ingredients.
Ingredients are listed in the descending order required by India Cosmetics Rules 2020.
Standards & Compliance
Usage warnings and directions are clear on the label.
Contains a retinoid (retinyl) - generally advised against during pregnancy. Not a general-safety issue.
Screened against a curated reference set that we are continuing to verify and expand, so “clear” means no flag from that set, not a guarantee. Not a substitute for a full toxicological or clinical assessment.
| Ingredient |
|---|
Aqua/Water/Eau |
Dimethicone |
Niacinamide |
Glycerin |
Propylene Glycol |
Polysilicone-11 |
Silica |
Bis-PEG/PPG-16/16 PEG/PPG-16/16 Dimethicone |
Cystoseira TamariscIfolia Extract |
2-Mercaptonicotinoyl Glycine |
PEG-20 Methyl Glucose Sesquistearate |
Sodium Hyaluronate |
Sodium Hydroxide |
Sodium Thiosulfate |
Carnosine |
Poloxamer 338 |
Ammonium Polyacryloyldimethyl Taurate |
Dipotassium Glycyrrhizate |
Caprylic/Capric Triglyceride |
Capryloyl Salicylic Acid |
Caprylyl Glycol |
Citric Acid |
Trisodium Ethylenediamine Disuccinate |
Xanthan Gum |
Pentylene Glycol |
Octyldodecanol |
Retinyl Palmitate |
Tocopherol |
Pentaerythrityl Tetra-Di-T-Butyl Hydroxyhydrocinnamate |
Phenoxyethanol |
Ci 17200/Red 33 |
Parfum/Fragrance |
INCI order as declared on packaging. Position reflects approximate concentration (high to low).
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
Flags are based on publicly available INCI only. Not a substitute for full regulatory compliance review.
Supported by the presence of Niacinamide, Melasyl™, LHA, and Retinyl Palmitate, and brand's clinical study summary for dark spot reduction.
Evidence visible
Brand states 'Clinically proven to reduce dark spots by 85% in 8 weeks' based on a clinical study summary.
Evidence visible
Brand claims 'long-lasting efficacy' and 'prevents reappearance' based on clinical study summary, but specific data on prevention is less detailed than reduction.
Evidence visible
Niacinamide is high in the INCI, consistent with 10% disclosure. Melasyl™ (2-Mercaptonicotinoyl Glycine) is also high in the INCI. Percentages are disclosed.
Mentioned only
Brand states 'Clinically proven to reduce dark spots by 85% in 8 weeks' based on a clinical study summary.
Evidence visible
Brand provides summary results of a clinical study (e.g., '85% reduction in 8 weeks'). Full study details (DOI, methodology) are not publicly linked on the Indian site, but summary is present.
Evidence visible
Standard claim for LRP products, implying testing under dermatological supervision. Summary of testing is typically available from the brand.
Evidence visible
Standard claim for LRP products, implying testing to ensure it does not clog pores. Summary of testing is typically available from the brand.
Evidence visible
Standard claim for LRP products, implying formulation to minimize allergic reactions. Summary of testing is typically available from the brand.
Evidence visible
Supported by the gentle nature of the actives (Niacinamide, Melasyl, LHA) and LRP's focus on sensitive skin, reducing risk of post-inflammatory hyperpigmentation.
Evidence visible
This review evaluates brand claims against visible evidence and formula logic. It does not replace a full ingredient safety analysis or a clinical product test. Results vary by individual, and the consumer should always read the full ingredient list and follow usage guidance.
Are you the brand? If you have published test data or want to request a re-review, write to us at hello@thecleansheet.in.
No IARC-classified or formaldehyde-releasing ingredient found in the database screen.
No commonly-comedogenic ingredient found - a reasonable fit for acne-prone skin.
Irritation & Allergen Risk
Declares 1 known allergen(s) (Retinyl Palmitate). Reactive skin should note these.
No high-sensitisation preservative (MI/MCI/formaldehyde-releaser) from our screen was found.
Brand claims dermatologist testing (claim stated; underlying report not seen).
Ingredient Transparency
The full INCI list is publicly available, not just hero ingredients.
Active percentages are disclosed for the hero ingredient(s).
Any proprietary 'complex' is broken down into its actual ingredients.
Ingredients are listed in the descending order required by India Cosmetics Rules 2020.
Standards & Compliance
Usage warnings and directions are clear on the label.
Contains a retinoid (retinyl) - generally advised against during pregnancy. Not a general-safety issue.
Screened against a curated reference set that we are continuing to verify and expand, so “clear” means no flag from that set, not a guarantee. Not a substitute for a full toxicological or clinical assessment.
Niacinamide is high in the INCI, consistent with 10% disclosure. Melasyl™ (2-Mercaptonicotinoyl Glycine) is also high in the INCI. Percentages are disclosed.
Brand states 'Clinically proven to reduce dark spots by 85% in 8 weeks' based on a clinical study summary.
Brand provides summary results of a clinical study (e.g., '85% reduction in 8 weeks'). Full study details (DOI, methodology) are not publicly linked on the Indian site, but summary is present.
Standard claim for LRP products, implying testing under dermatological supervision. Summary of testing is typically available from the brand.
Standard claim for LRP products, implying testing to ensure it does not clog pores. Summary of testing is typically available from the brand.
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
No prohibited or restricted ingredients identified
Flags are based on publicly available INCI only. Not a substitute for full regulatory compliance review.
Supported by the presence of Niacinamide, Melasyl™, LHA, and Retinyl Palmitate, and brand's clinical study summary for dark spot reduction.
Evidence visible
Brand states 'Clinically proven to reduce dark spots by 85% in 8 weeks' based on a clinical study summary.
Evidence visible
Brand claims 'long-lasting efficacy' and 'prevents reappearance' based on clinical study summary, but specific data on prevention is less detailed than reduction.
Evidence visible
Niacinamide is high in the INCI, consistent with 10% disclosure. Melasyl™ (2-Mercaptonicotinoyl Glycine) is also high in the INCI. Percentages are disclosed.
Mentioned only
Brand states 'Clinically proven to reduce dark spots by 85% in 8 weeks' based on a clinical study summary.
Evidence visible
Brand provides summary results of a clinical study (e.g., '85% reduction in 8 weeks'). Full study details (DOI, methodology) are not publicly linked on the Indian site, but summary is present.
Evidence visible
Standard claim for LRP products, implying testing under dermatological supervision. Summary of testing is typically available from the brand.
Evidence visible
Standard claim for LRP products, implying testing to ensure it does not clog pores. Summary of testing is typically available from the brand.
Evidence visible
Standard claim for LRP products, implying formulation to minimize allergic reactions. Summary of testing is typically available from the brand.
Evidence visible
Supported by the gentle nature of the actives (Niacinamide, Melasyl, LHA) and LRP's focus on sensitive skin, reducing risk of post-inflammatory hyperpigmentation.
Evidence visible
